Dashboard
Manage Tickers

REGNREGENERON PHARMACEUTICALS, ...

Nasdaq regeneron.com


$ 980.13 $ 10.25 (1.06 %)    

Friday, 31-May-2024 15:59:45 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 454.82 $ -0.84 (-0.19 %)
DIA $ 398.57 $ 6.05 (1.59 %)
SPY $ 530.36 $ 4.76 (0.91 %)
TLT $ 91.26 $ 0.61 (0.68 %)
GLD $ 225.37 $ -1.27 (-0.59 %)
$ 980.16
$ 967.77
$ 976.52 x 100
$ 998.14 x 130
$ 967.77 - $ 980.41
$ 684.81 - $ 998.33
812,914
na
112.82B
$ 0.53
$ 29.24
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-02-2024 03-31-2024 10-Q
2 02-05-2024 12-31-2023 10-K
3 11-02-2023 09-30-2023 10-Q
4 08-03-2023 06-30-2023 10-Q
5 05-04-2023 03-31-2023 10-Q
6 02-06-2023 12-31-2022 10-K
7 11-03-2022 09-30-2022 10-Q
8 08-03-2022 06-30-2022 10-Q
9 05-04-2022 03-31-2022 10-Q
10 02-07-2022 12-31-2021 10-K
11 11-04-2021 09-30-2021 10-Q
12 08-05-2021 06-30-2021 10-Q
13 05-06-2021 03-31-2021 10-Q
14 02-08-2021 12-31-2020 10-K
15 11-05-2020 09-30-2020 10-Q
16 08-05-2020 06-30-2020 10-Q
17 05-05-2020 03-31-2020 10-Q
18 02-07-2020 12-31-2019 10-K
19 11-05-2019 09-30-2019 10-Q
20 08-06-2019 06-30-2019 10-Q
21 05-07-2019 03-31-2019 10-Q
22 02-07-2019 12-31-2018 10-K
23 11-06-2018 09-30-2018 10-Q
24 08-02-2018 06-30-2018 10-Q
25 05-03-2018 03-31-2018 10-Q
26 02-08-2018 12-31-2017 10-K
27 11-08-2017 09-30-2017 10-Q
28 08-03-2017 06-30-2017 10-Q
29 05-04-2017 03-31-2017 10-Q
30 02-09-2017 12-31-2016 10-K
31 11-04-2016 09-30-2016 10-Q
32 08-04-2016 06-30-2016 10-Q
33 05-05-2016 03-31-2016 10-Q
34 02-11-2016 12-31-2015 10-K
35 11-04-2015 09-30-2015 10-Q
36 08-04-2015 06-30-2015 10-Q
37 05-07-2015 03-31-2015 10-Q
38 02-12-2015 12-31-2014 10-K
39 11-04-2014 09-30-2014 10-Q
40 08-05-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

fda-extends-review-deadline-for-regeneronsanofis-dupixent-for-smokers-lungs-disease
FDA Extends Review Deadline For Regeneron/...
05/31/2024 13:23:50

The FDA extends the target action date for reviewing Dupixent as an add-on treatment for uncontrolled COPD to September 27, 202...

Core News & Articles
Sanofi And Regeneron Pharmaceuticals' Dupi...
05/31/2024 06:34:29

Dupixent recommended for EU approval by the CHMP to treat patients with COPD Recommendation for adults with uncontrolled COP...

Core News & Articles
FDA Extends Priority Review Deadline For R...
05/31/2024 05:55:36

The US Food and Drug Administration (FDA) has extended by three months the target action date of its priority review of the sup...

whats-going-on-with-biohaven-stock-wednesday
What's Going On With Biohaven Stock Wednes...
05/29/2024 16:03:45

The company announced it dosed a patient with a new possible treatment for certain cancers, showcased positive data from two di...

after-unitedhealth-cyberattack-drug-distributor-cencora-notifies-americans-health-information-stolen-in-data-breach-in-february
After UnitedHealth Cyberattack, Drug Distr...
05/24/2024 16:00:24

Cencora reports a cyberattack exposing sensitive medical information, including patient names, addresses, birth dates, diagnose...

regn---analyzing-regeneron-pharmaceuticalss-short-interest
(REGN) - Analyzing Regeneron Pharmaceutica...
05/20/2024 19:15:23

Core News & Articles
Regeneron Pharmaceuticals And Sanofi Prese...
05/20/2024 18:17:57

NOTUS results confirm landmark data from the Phase 3 BOREAS trial and show Dupixent significantly reduced exacerbations by 34% ...

insights-into-regeneron-pharmaceuticalss-performance-versus-peers-in-biotechnology-sector
Insights Into Regeneron Pharmaceuticals's ...
05/17/2024 15:00:51

heres-how-much-you-would-have-made-owning-regeneron-pharmaceuticals-stock-in-the-last-10-years
Here's How Much You Would Have Made Owning...
05/14/2024 14:30:25

evercore-isi-group-initiates-coverage-on-regeneron-pharmaceuticals-with-outperform-rating-announces-price-target-of-1150
Evercore ISI Group Initiates Coverage On R...
05/14/2024 09:13:39

Evercore ISI Group analyst Cory Kasimov initiates coverage on Regeneron Pharmaceuticals (NASDAQ:REGN) with a Outperform rati...

Core News & Articles
Regeneron Pharmaceuticals And Sanof's Dupi...
05/13/2024 07:00:51

If approved, Dupixent would be the first treatment in the U.S. indicated for adolescents aged 12-17 years with inadequately c...

regeneron-announces-prelim-data-in-an-asgct-presentation-showing-db-oto-improved-hearing-to-normal-levels-in-one-child-within-24-weeks-initial-hearing-improvements-observed-in-a-second-child-at-6-week-assessment
Regeneron Announces Prelim. Data In An ASG...
05/08/2024 10:03:41

assessing-regeneron-pharmaceuticals-insights-from-16-financial-analysts
Assessing Regeneron Pharmaceuticals: Insig...
05/03/2024 16:00:21

cantor-fitzgerald-reiterates-neutral-on-regeneron-pharmaceuticals-maintains-925-price-target
Cantor Fitzgerald Reiterates Neutral on Re...
05/03/2024 15:27:50

Cantor Fitzgerald analyst Olivia Brayer reiterates Regeneron Pharmaceuticals (NASDAQ:REGN) with a Neutral and maintains $925...

regeneron-pharmaceuticals-targets-quality-weight-loss-in-latest-obesity-innovation
Regeneron Pharmaceuticals Targets Quality ...
05/02/2024 19:49:45

Regeneron Pharmaceuticals Q1 2024 earnings: EPS down 5%, sales miss; Eylea US sales drop 16%, Dupixent offsets. Oncology treatm...

wall-street-inches-up-after-powells-inflation-remarks-chipmakers-rebound-gold-crude-falter-whats-driving-markets-thursday
Wall Street Inches Up After Powell's Infla...
05/02/2024 17:37:33

U.S. stock markets surged during Thursday’s midday trading session in New York, with major averages all showing gains.

industry-comparison-evaluating-regeneron-pharmaceuticals-against-competitors-in-biotechnology-industry
Industry Comparison: Evaluating Regeneron ...
05/02/2024 15:00:43

heres-how-much-you-would-have-made-owning-regeneron-pharmaceuticals-stock-in-the-last-20-years
Here's How Much You Would Have Made Owning...
05/02/2024 14:30:22

regeneron-pharmaceuticals-q1-2024-adj-eps-955-misses-1010-estimate-sales-3145b-miss-3221b-estimate
Regeneron Pharmaceuticals Q1 2024 Adj EPS ...
05/02/2024 10:31:29

Regeneron Pharmaceuticals (NASDAQ:REGN) reported quarterly earnings of $9.55 per share which missed the analyst consensus estim...

10-health-care-stocks-with-whale-alerts-in-todays-session
10 Health Care Stocks With Whale Alerts In...
04/30/2024 17:35:25

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION